Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ Vaccine Safety and Efficacy in Healthy Malian Adults
NCT02627456Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2015
- Primary completion
- Mar 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sanaria PfSPZ Vaccine in malaria (7 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Duration of Protection and Safety. Started Dec 2015; status: completed.
02
Drugs
Sanaria PfSPZ Vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02627456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627456.